| Identification | Back Directory | [Name]
C2 L-erythro Ceramide (d18:1/2:0) | [CAS]
150338-90-2 | [Synonyms]
Acetyl-L-erythro-sphingosine
C2 L-erythro Ceramide (d18:1/2:0)
Acetamide, N-[(1R,2S,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]- | [Molecular Formula]
C20H39NO3 | [MOL File]
150338-90-2.mol | [Molecular Weight]
341.53 |
| Chemical Properties | Back Directory | [Boiling point ]
532.4±50.0 °C(Predicted) | [density ]
0.964±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Chloroform: soluble; DMF: soluble; DMSO: soluble; Ethanol: soluble; Methanol: soluble | [form ]
A solid | [pka]
13.50±0.20(Predicted) |
| Hazard Information | Back Directory | [Description]
C2 L-erythro Ceramide is a bioactive sphingolipid and a cell-permeable analog of naturally occurring ceramides. It stimulates cholesterol efflux in CHO cells expressing the human ABCA1 receptor when used at a concentration of 10 μM, however, this efflux is >50% less than that stimulated by C2 ceramide . C2 L-erythro Ceramide also induces cell cycle arrest in the G0\G1 phase and a 50-fold increase in sphingosine accumulation as well as inhibits growth of HL-60 leukemia cells. [Matreya, LLC. Catalog No. 1847] | [Uses]
C2 L-Erythro ceramide (d18:1/2:0) is a cell-permeable sphingolipid. C2 L-Erythro ceramide (d18:1/2:0) induces cell cycle arrest in the G0/G1 phase and inhibits cell growth[1][2]. | [References]
[1] Baek MY, et al. Sphingolipid metabolic changes during chiral C2-ceramides induced apoptosis in human leukemia cells. Arch Pharm Res. 2001 Apr;24(2):144-9. DOI:10.1007/BF02976482
[2] Bielawska A, et al. Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide. J Biol Chem. 1993;268(35):26226-26232. PMID:8253743 |
|
| Company Name: |
Alfa Chemistry
|
| Tel: |
1-516-6625404 |
| Website: |
https://www.alfa-chemistry.com |
| Company Name: |
Enzo Biochem Inc
|
| Tel: |
Enzo Biochem Inc. 13797054060 |
| Website: |
www.enzo.com |
|